Skip to main content

2 Result(s)

within N. Uboha Remove this filter

and

  1. Article

    Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

    H. S. Hochster, N. Uboha, W. Messersmith… in Cancer Chemotherapy and Pharmacology (2015)

    Download PDF (102 KB) View Article

  2. No Access

    Article

    Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer

    More than half of colorectal tumors harbor activating mutations in RAS/RAF proteins. Selumetinib (AZD6244, ARRY-142886) is a small molecule kinase inhibitor targeting MEK kinase, downstream of RAS. We examined...

    H. S. Hochster, N. Uboha, W. Messersmith… in Cancer Chemotherapy and Pharmacology (2015)